Premium
Effects of ΔNp73β on cisplatin treatment in colon cancer cells
Author(s) -
Lööf Jasmine,
Pfeifer Daniella,
Ding Zhenyu,
Sun XiaoFeng,
Zhang Hong
Publication year - 2012
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.20835
Subject(s) - cisplatin , biology , transactivation , clonogenic assay , viability assay , apoptosis , transfection , mutant , cancer research , downregulation and upregulation , cancer cell , cell culture , gene isoform , cell , wild type , microbiology and biotechnology , cancer , gene , transcription factor , chemotherapy , genetics
Abstract p73 can activate transcription of p53‐responsive genes, thereby inhibiting cell growth. An alternative promoter in the TP73 gene gives rise to an N‐terminally truncated isoform of p73, ΔNp73, which lacks the transactivation domain of the full length TAp73 protein. TAp73 is considered pro‐apoptotic, and ΔNp73 anti‐apoptotic. In this study, we overexpressed ΔNp73β in p53 wild type and p53 mutant colon cancer cell lines and further exposed the cells to cancer therapeutic drug cisplatin. The results showed that cisplatin decreased the protein expression levels of ΔNp73β in a dose‐dependent manner, and both TAp73 and p53 were upregulated after cisplatin treatment. Further, clonogenic potential and cell viability were decreased, and apoptotic cells increased, in p53 mutant and in p53 wild type cells. Cellular viability was significantly higher in ΔNp73β‐cells than mock‐transfected cells. However, ΔNp73β overexpression did not affect the cellular susceptibility to cisplatin. In conclusion, the overexpression of ΔNp73β increases viability in p53 wild type and p53 mutant colon cancer cells, and cisplatin induces the degradation of ΔNp73β in a dose‐dependent manner. © 2011 Wiley Periodicals, Inc.